Cagent Vascular Unveils New Serranator SL-PRO Product for CLTI and Pedal Disease
Cagent Vascular Announces the Launch of Serranator SL-PRO™ for Pedal and Tibial Disease Treatment Cagent Vascular a leader in the development of cutting-edge serration technology for vessel dilation in endovascular…
Enveric Biosciences Completes $5 Million Public Offering
Enveric Biosciences Completes $5 Million Public Offering Enveric Biosciences a leading biotechnology company focused on the development of groundbreaking neuroplastogenic small-molecule therapeutics, has made a significant advancement in its efforts…
Patient-Centric Medidata Pioneers AI-Driven Innovations
Patient-Centric Medidata Leading the Future of Life Sciences with AI-Powered Innovations and Patient-Centric Experiences Patient-Centric Medidata, a Dassault Systèmes brand, continues to solidify its role as a pioneering force in…
Algiax Reports Positive Phase 2a Results for AP-325 in Neuropathic Pain
Reports Algiax Pharmaceuticals Announces Positive Phase 2a Results for AP-325 in Neuropathic Pain Reports Algiax Pharmaceuticals, a clinical-stage biotechnology company dedicated to developing innovative therapies for chronic neuropathic pain, has…
NSCLC Patients Nuvation Bio Launches U.S. Expanded Access Program for Taletrectinib in ROS1
Nuvation Bio Expands Access to Taletrectinib for Advanced ROS1-Positive NSCLC Patients in the U.S. Nuvation Bio a leading global biopharmaceutical company focused on developing innovative therapies for some of the…
DNAnexus Strengthens Veeva Partnership for Global Regulatory Collaboration
DNAnexus Expands Relationship with Veeva to Advance Global Regulatory Collaboration DNAnexus, a global leader in regulatory cloud services, has announced the expansion of its collaboration with Veeva Systems, a prominent…
Nucleic Acid Solutions TriLink BioTechnologies® and Avantor® Partner to Expand Access in Europe
TriLink BioTechnologies® and Avantor® Partner to Expand Nucleic Acid Solutions in Europe TriLink BioTechnologies a Maravai® LifeSciences company and a global leader in providing cutting-edge life science reagents and services,…
D&D Pharmatech Completes Enrollment for 48-Week Phase 2 Trial of DD01 in MASH
D&D Pharmatech a clinical-stage biotechnology company dedicated to the development of disease-modifying therapeutics, has announced the successful completion of patient enrollment for DD01-DN-2, an ongoing Phase 2 clinical trial. This…
AdvanCell Closes Oversubscribed $112M Series C Funding
AdvanCell Closes Oversubscribed $112M Series C Funding AdvanCell, a pioneering clinical-stage radiopharmaceutical company focused on developing groundbreaking cancer therapeutics, has announced the successful closure of an oversubscribed US$112 million Series…
Cosette Pharmaceuticals Names Brad Leonard VP of Generics Commercial Operations
Cosette Pharmaceuticals a leading specialty pharmaceuticals company, has announced the appointment of Brad Leonard as Vice President, Generics Commercial Operations. This strategic move comes as the company continues its expansion…
Bayer Heart Failure Seeks EU Approval for Finerenone in Heart Failure
Bayer has officially submitted a marketing authorization application to the European Medicines Agency (EMA), seeking approval for the use of finerenone in adult patients with heart failure (HF) with a…
Cystic Fibrosis Biotech Sionna Announces Groundbreaking $150M IPO for Treatment Development
Sionna Therapeutics Announces $150M IPO to Advance Cystic Fibrosis Drug Development Sionna Therapeutics, a Massachusetts-based biotechnology company specializing in cystic fibrosis (CF) treatments, has officially announced the terms of its…